Drug Trial Radar · NCT00031902
Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma
Last checked: Nov 19, 2026Latest source record: Sep 20, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
Not stated
Start
Oct 2001
Primary completion
Not stated
Sponsor
- Lead sponsor
- Lymphoma Trials OfficeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 27, 2003
Design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining rituximab with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of rituximab plus combination chemotherapy in treating patients who have HIV-related non-Hodgkin's lymphoma.
Conditions
- Lymphoma
Interventions
bleomycin sulfateBiological
rituximabBiological
prednisoloneDrug
vincristine sulfateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Chelsea Westminster Hospital
London, United Kingdom
St. George's Hospital
London, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.